- Chronic Fatigue Syndrome
- Lyme's Disease
- Alcohol Detox
- Rheumatoid Arthritis
Low Level Laser Therapy is scientifically well documented for many indications; there are more than 100 double-blind positive studies confirming the clinical effect of LLLT. More than 2500 research reports are published. In 2005 the Postgraduate Medical Journal (81:436-441) published a scientific review of 100 scientific studies from Eastern Europe on the use of blood irradiation in the treatment of The study was conducted by T Moshkovska , J Mayberry from the Leicester General Hospital, Leicester, UK. The study was published under the name " It is time to test low level laser therapy in Great Britain" . The authors of the study have come to following conclusion: "The ability to non-thermally and non-destructively change cell function is known as laser bio-stimulation and is the basis for the current use of lasers in a number of medical fields. The worldwide interest in LLLT is illustrated by its use in more than 85 institutions in over 37 countries. Since the first study was reported in 1967, some 2500 papers have been published in a range of journals worldwide and the value of LLLT is much better reported than many believe. Its scientific background is sound enough to say that it is both safe and effective." T Moshkovska and J Mayberry, Postgraduate Medical Journal 2005; 81: 436-441 © 2005 Fellowship of Postgraduate Medicine.
For more information on the scientific research please refer to the book:
Michael Weber, Medical Low-Level-Therapy – Foundation and Clinical Applications, 2. Edition, 2015, ISLA Research Group Laser Therapy - Clinical Practice and Scientific Background by Jan Tuner and Lars Hode, or visit the research library on the website Tina Karu, The Science of Low-Power-Laser Therapy
The NAD+ coenzyme was first discovered by British biochemists Arthur Harden and William John Young in 1906. They noticed adding boiled and filtered yeast extract accelerated alcoholic fermentation greatly in unboiled yeast extracts. They called the unidentified factor responsible for this effect a coferment.
Vitamin precursors of NAD+ were identified in 1938, when Conrad Elvehjem showed that live r has an "anti-black tongue" activity in the form of nicotinamide.
Then, in 1939, first strong evidence was found that niacin is used to synthesize NAD+. In the early 1940s, Arthur Kornberg made another important contribution towards understanding NAD+ metabolism, by being the first to detect an enzyme in the biosynthetic pathway.
The metabolism of NAD+ has remained an area of intense research into the 21st century, with interest being heightened after the discovery of the NAD+-dependent protein deacetylases called sirtuins in 2000, by Shin-ichiro Imai and coworkers at the Massachusetts Institute of Technology.
For the full benefit of NAD+ therapy, it's very important that the highest grade of NAD+ and its sterility is used its advisable to check the cert of analysis.
What used to take up to 6 hours for a NAD+ infusion, can now be systematically delivered in 35 minutes as a result of many years experience with NAD+.